Department of Surgery, Yokohama City University, Yokohama, Japan;
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
Anticancer Res. 2024 Apr;44(4):1335-1351. doi: 10.21873/anticanres.16930.
For resectable colorectal cancer (CRC), the standard treatment is perioperative adjuvant treatment and complete resection. For unresectable CRC, the standard treatment is systemic chemotherapy. The detection of promising biomarkers is necessary for optimizing the management of CRC and improving patient survival. If physicians can detect useful biomarkers, patients with CRC may benefit from more aggressive or less toxic treatment. Recent studies have shown that the inflammatory and nutritional status both influence the short and long-term oncological outcomes of patients with CRC during perioperative and/or chemotherapy. The utility of several tools for the evaluation of the inflammation and nutritional status has been reported. The introduction of such tools in the management of CRC could have a beneficial impact on postoperative surgical complications or adverse events of chemotherapy. An understanding of the characteristics of each of these evaluations is necessary for their introduction in daily clinical practice. The present report summarizes the background and current status of nutrition and inflammation evaluation tools and future perspectives on their application in the management of patients with CRC.
对于可切除的结直肠癌(CRC),标准治疗是围手术期辅助治疗和完全切除。对于不可切除的 CRC,标准治疗是全身化疗。发现有前途的生物标志物对于优化 CRC 的管理和提高患者生存率是必要的。如果医生能够检测到有用的生物标志物,CRC 患者可能会受益于更积极或毒性更小的治疗。最近的研究表明,炎症和营养状况都影响 CRC 患者围手术期和/或化疗期间的短期和长期肿瘤学结局。已经报道了几种用于评估炎症和营养状况的工具的效用。将这些工具引入 CRC 的管理中可能会对术后手术并发症或化疗的不良事件产生有益影响。了解这些评估的各自特点对于将其引入日常临床实践是必要的。本报告总结了营养和炎症评估工具的背景和现状,以及它们在 CRC 患者管理中的应用的未来展望。